VBI Vaccines (NASDAQ:VBIV) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIVFree Report) in a research note released on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Price Performance

VBI Vaccines stock opened at $0.60 on Friday. The stock has a fifty day moving average of $0.61 and a two-hundred day moving average of $0.62. VBI Vaccines has a fifty-two week low of $0.45 and a fifty-two week high of $3.47.

VBI Vaccines (NASDAQ:VBIVGet Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.85 million. VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. Research analysts predict that VBI Vaccines will post -1.23 earnings per share for the current year.

VBI Vaccines Company Profile

(Get Free Report)

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

Featured Articles

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.